PubRank

Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation (RED-AF)

Clinical Trial ID NCT04357288

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04357288

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 39.97
2 Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 28.99
3 Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001 24.12
4 Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011 23.50
5 Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998 19.93
6 Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2013 12.44
7 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012 12.36
8 Validation of a decisional conflict scale. Med Decis Making 1995 12.19
9 Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007 10.87
10 Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014 10.06
11 Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004 8.80
12 Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011 8.75
13 Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2014 8.74
14 Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987 8.09
15 Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999 7.74
16 Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013 7.70
17 Decision making during serious illness: what role do patients really want to play? J Clin Epidemiol 1992 6.66
18 The Control Preferences Scale. Can J Nurs Res 1997 6.28
19 Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005 5.92
20 Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007 5.89
21 Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996 5.41
22 Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978 5.37
23 Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA 2011 4.73
24 The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med 2009 4.41
25 Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2010 4.16
26 Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010 4.15
27 Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003 4.13
28 Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996 4.11
29 Validation of a decision regret scale. Med Decis Making 2003 3.70
30 Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009 3.68
31 Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2014 3.53
32 Can simple clinical measurements detect patient noncompliance? Hypertension 1981 3.29
33 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014 3.28
34 Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011 3.25
35 The OPTION scale: measuring the extent that clinicians involve patients in decision-making tasks. Health Expect 2005 3.18
36 Patient participation in deciding breast cancer treatment and subsequent quality of life. Med Decis Making 1997 3.14
37 Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med 2007 2.82
38 Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011 2.80
39 Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008 2.73
40 The 9-item Shared Decision Making Questionnaire (SDM-Q-9). Development and psychometric properties in a primary care sample. Patient Educ Couns 2009 2.07
41 Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med 2011 1.84
42 Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012 1.79
43 Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J 2014 1.54
44 The Statin Choice decision aid in primary care: a randomized trial. Patient Educ Couns 2009 1.38
45 Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013 1.37
46 Validation of a preparation for decision making scale. Patient Educ Couns 2009 1.19
47 Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2012 1.15
48 Patient participation in treatment decision making and the psychological consequences of breast cancer surgery. Womens Health 1998 1.05
49 Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology 2013 0.99
50 Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015 0.95
51 Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One 2013 0.93
52 Pathophysiological determinants of worse stroke outcome in atrial fibrillation. Cerebrovasc Dis 2010 0.92
53 The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients. Health Qual Life Outcomes 2012 0.87
54 How pediatricians counsel parents when no "best-choice" management exists: lessons to be learned from hypoplastic left heart syndrome. Arch Pediatr Adolesc Med 2004 0.84
55 Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation. Stroke 2011 0.80
56 Patients' experiences of communication and involvement in decision-making about atrial fibrillation treatment in consultations with nurses and physicians. Scand J Caring Sci 2015 0.79
57 The association between patient-reported medication adherence and anticoagulation control. Am J Med 2017 0.75
58 Informed consent and hypoplastic left heart syndrome. Acta Paediatr 2005 0.75
59 International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J 2017 0.75
Next 100